相关临床试验
440
26 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
10
2.3%
Approved For Marketing
1
0.2%
已完成
289
65.7%
Enrolling By Invitation
1
0.2%
No Longer Available
3
0.7%
尚未招募
15
3.4%
招募中
69
15.7%
终止
23
5.2%
Unknown
1
0.2%
撤回
28
6.4%
暂无批准数据
- Researchers at UT Health San Antonio found that the liver's internal circadian clock controls the timed release of metabolism-regulating signaling proteins, published in Nature Communications. - The liver protein endostatin proved most effective at promoting fat breakdown when released on its natural daily rhythm, suggesting time-of-day dosing could matter for future therapies. - Irregular eating and disrupted sleep are linked to higher risks of obesity, diabetes, and other metabolic disorders, underscoring the clinical relevance of circadian coordination. - The team aims to develop novel peptides to find "the next GLP-1 drug, or even something better," according to senior author Kevin Koronowski, PhD.
- Non-linear modeling of 2,410 Framingham Heart Study participants revealed that regularly sleeping 8.5 hours or more per night is associated with elevated plasma p-tau181, a hallmark Alzheimer's protein. - The association with p-tau181 remained significant after adjusting for age, sex, sleep apnea, depression, kidney function, and APOE ε4 genotype, while three other neurodegeneration biomarkers lost significance. - Researchers emphasize long sleep is likely a behavioral footprint of early neurodegeneration, not a cause of Alzheimer's disease, given the cross-sectional study design. - Clinicians are advised that older adults routinely requiring 9–10 hours of sleep should prompt conversations about sleep quality and brain health monitoring.
- The FDA has approved three breakthrough breast cancer treatments that can now be used in earlier stages of the disease (stages two and three), expanding beyond their previous use in late-stage patients. - Datroway received approval for adults with triple negative breast cancer, delivering medication directly to cancer cells with improved effectiveness and reduced toxicity compared to traditional chemotherapy. - Enhertu gained two separate approvals: one for shrinking or eliminating cancer before surgery, and another for patients with residual disease following surgery to reduce recurrence risk. - These approvals represent a significant advancement for the one in eight women who will develop breast cancer, offering both longer survival and better quality of life with less toxic treatments.
• Researchers at UT Health San Antonio have developed "chemical endocytic medicinal chemistry," a novel approach that could enable large-molecule drugs to be taken orally rather than intravenously. • The discovery leverages CD36 protein receptors on cell surfaces to facilitate cellular uptake of large and water-soluble drugs, potentially overcoming the blood-brain barrier for treating conditions like brain cancer and Alzheimer's disease. • This paradigm shift in drug delivery could revolutionize pharmaceutical development, resurrect previously abandoned drug candidates, and enable more personalized medicine based on patients' varying CD36 expression levels.
- A Phase 1 trial led by UT Health San Antonio demonstrated that Rhenium Obisbemeda more than doubled median survival time to 17 months in recurrent glioblastoma patients receiving high doses, compared to the typical 8-month survival. - The investigational drug uses nanoliposome technology to deliver targeted radiation directly to brain tumors via convection enhanced delivery (CED), bypassing the blood-brain barrier while sparing healthy tissue. - Plus Therapeutics' Rhenium Obisbemeda recently received FDA Orphan Drug Designation for treating leptomeningeal metastases in lung cancer patients, with Phase 2 trials for glioblastoma expected to complete by year-end.
- Researchers from UT Health San Antonio and Tulane University have developed a new drug candidate that effectively eliminates senescent "zombie cells" from the liver, showing potential for treating MASLD and liver cancer. - The drug targets BCL-xl and BCL-2 proteins to induce senescent cell death, demonstrating superior efficacy in reducing liver damage and cancer growth compared to existing senolytics, with fewer side effects. - The breakthrough discovery addresses a critical healthcare need in San Antonio, where MASLD prevalence is high due to elevated rates of obesity and diabetes in the community.
- PharmAla Biotech will supply both 40mg and new 20mg LaNeo MDMA capsules for a Department of Defense-funded PTSD treatment trial targeting active-duty military personnel. - The STRONG STAR Consortium at UT Health San Antonio secured $10M in Defense Appropriations Act funding to conduct groundbreaking research on MDMA-Assisted Therapy for military populations. - The study represents one of the first investigations into MDMA-Assisted Therapy specifically designed for active-duty military personnel, with trials to be conducted at UT Health San Antonio and Emory University.
- A recent study reveals that a smartphone app, when used with medication for opioid use disorder (MOUD), significantly reduces opioid use among patients. - The research indicates that patients using the app alongside MOUD reported 35% fewer days of opioid use compared to those receiving MOUD alone. - The study also found that app users remained in treatment nearly 19% longer, highlighting the app's potential to improve patient retention. - The WEconnect Health CM app offers contingency management and recovery support, providing a comprehensive approach to opioid use disorder treatment.
- A new neuroimaging marker, peak-width of skeletonized mean diffusivity (PSMD), correlates with general cognition and may identify individuals at risk of dementia. - The study found that higher PSMD values were associated with lower general cognitive function, independent of age, sex, education and intracranial volume. - PSMD demonstrates excellent instrumental properties and biological validation, making it a potential biomarker for clinical trials related to vascular contributions to cognitive impairment and dementia (VCID). - Researchers suggest PSMD's non-invasive, automated, and reliable nature makes it ideal for assessing cerebral small vessel diseases in dementia studies.
- Dr. Marzieh Salehi challenges the myth that obesity is solely caused by calorie imbalance, emphasizing the role of gut-organ communication. - A clinical trial will study semaglutide's impact on blood glucose regulation in spinal cord injury patients with type 2 diabetes. - Research aims to understand how semaglutide affects gut-organ communication, potentially leading to precision medicine approaches for metabolic conditions. - The NIH-funded study seeks to uncover specific communication issues in high-risk populations, like those with spinal cord injuries.
